196 filings
Page 6 of 10
424B5
dvj0ky u1h
4 Oct 22
Prospectus supplement for primary offering
8:52am
6-K
prtusszm24tz7ar
23 Sep 22
Current report (foreign)
8:18am
6-K
jf6bn6
21 Sep 22
Important Milestone Reached for Evaxion Biotech’s EVX-01 Personalized Cancer Therapy
11:43am
424B4
a9v9bj61t e9
30 Aug 22
Prospectus supplement with pricing info
4:52pm
EFFECT
khddo6bo7svx
29 Aug 22
Notice of effectiveness
12:15am
CORRESP
kfk60
24 Aug 22
Correspondence with SEC
12:00am
F-1/A
4n23b
22 Aug 22
Registration statement (foreign) (amended)
4:40pm
6-K
4o0znvotqgc4
11 Aug 22
Current report (foreign)
4:30pm
6-K
0f8hfm9thr70x
10 Aug 22
Evaxion Biotech Announces Second Quarter 2022 Financial Results and Provides Business Update
12:00am
6-K
uxf670
2 Aug 22
Evaxion Biotech A/S Announces Executive Management Changes
7:13am
UPLOAD
xn0thwixm
12 Jul 22
Letter from SEC
12:00am
F-1
j2teudcb2qtn29
7 Jul 22
Registration statement (foreign)
4:45pm
6-K
3j81z5 vs
1 Jul 22
Current report (foreign)
5:09pm
6-K
zp9ve7 lde
30 Jun 22
Evaxion Biotech Announces Gonorrhea as Second Bacterial Product Target
7:00am
6-K
6zve12s31aw0paadth
23 Jun 22
Current report (foreign)
7:38am
6-K
taxt0wf6x910p1j
21 Jun 22
Current report (foreign)
4:47pm
6-K/A
uzkp0k lh68zrrdn
8 Jun 22
Current report (foreign) (amended)
8:14am
6-K
hqe1fo7gk8krpck6om
7 Jun 22
Evaxion Biotech Secures Equity Financing of up to $40 Million from Lincoln Park Capital
5:05pm
EFFECT
g6u2 pah9ytz3knnnr6
6 Jun 22
Notice of effectiveness
12:15am
CORRESP
93j55plkar8fmk0a
1 Jun 22
Correspondence with SEC
12:00am